Toshiyuki Kitai1, Kenya Yamanaka2, Naoko Sugimoto2, Osamu Inamoto2. 1. Department of Surgery, Kishiwada City Hospital, 1001 Gakuhara-cho, Kishiwada, Osaka, 596-8501, Japan. kitait@kuhp.kyoto-u.ac.jp. 2. Department of Surgery, Kishiwada City Hospital, 1001 Gakuhara-cho, Kishiwada, Osaka, 596-8501, Japan.
Abstract
PURPOSE: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS + HIPEC) is the active treatment for peritoneal carcinomatosis of appendiceal origin. However, surgical management is sometimes difficult in patients with a high-tumor burden. METHODS: A high-tumor burden was defined as a peritoneal cancer index (PCI) ≥ 28. Among 49 patients receiving CRS + HIPEC, 29 had a PCI ≥ 28. RESULTS: Complete cytoreduction (CC-0/1) was achieved in 20 of the 29 patients with a PCI ≥ 28 and in all 20 patients with a PCI < 28. Among the patients achieving CC-0/1, gastrectomy or total colectomy was performed more frequently, the hospital stay was longer and postoperative complications were more frequent in those with a PCI ≥ 28 than in those with a PCI < 28. If CC-0/1 was achieved, the overall survival was comparable between patients with a PCI ≥ 28 and a PCI < 28. However, the recurrence-free survival was significantly worse for patients with a PCI ≥ 28 than for those with a PCI < 28 (5-year survival: 73.7% vs. 5.9%). Patients with recurrence who underwent repeat CRS showed a better overall survival than those without repeat CRS. Among patients with a PCI ≥ 28, a performance status (PS) of 2/3 was a significant prognostic factor (hazard ratio = 5.132). CONCLUSIONS: In patients with a high-tumor burden undergoing CRS + HIPEC, postoperative complications were more frequent, and the recurrence rate was higher than in those without a high-tumor burden. Repeat CRS improved the survival of patients with recurrence. The PS was a key indicator when selecting patients suitable for aggressive resection.
PURPOSE: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS + HIPEC) is the active treatment for peritoneal carcinomatosis of appendiceal origin. However, surgical management is sometimes difficult in patients with a high-tumor burden. METHODS: A high-tumor burden was defined as a peritoneal cancer index (PCI) ≥ 28. Among 49 patients receiving CRS + HIPEC, 29 had a PCI ≥ 28. RESULTS: Complete cytoreduction (CC-0/1) was achieved in 20 of the 29 patients with a PCI ≥ 28 and in all 20 patients with a PCI < 28. Among the patients achieving CC-0/1, gastrectomy or total colectomy was performed more frequently, the hospital stay was longer and postoperative complications were more frequent in those with a PCI ≥ 28 than in those with a PCI < 28. If CC-0/1 was achieved, the overall survival was comparable between patients with a PCI ≥ 28 and a PCI < 28. However, the recurrence-free survival was significantly worse for patients with a PCI ≥ 28 than for those with a PCI < 28 (5-year survival: 73.7% vs. 5.9%). Patients with recurrence who underwent repeat CRS showed a better overall survival than those without repeat CRS. Among patients with a PCI ≥ 28, a performance status (PS) of 2/3 was a significant prognostic factor (hazard ratio = 5.132). CONCLUSIONS: In patients with a high-tumor burden undergoing CRS + HIPEC, postoperative complications were more frequent, and the recurrence rate was higher than in those without a high-tumor burden. Repeat CRS improved the survival of patients with recurrence. The PS was a key indicator when selecting patients suitable for aggressive resection.
Authors: William Jimenez; Armando Sardi; Carol Nieroda; Michelle Sittig; Vladimir Milovanov; Maria Nunez; Nail Aydin; Vadim Gushchin Journal: Ann Surg Oncol Date: 2014-07-02 Impact factor: 5.344
Authors: Riom Kwakman; Anne M Schrama; Josefien P van Olmen; René H Otten; Elly S de Lange-de Klerk; Erienne M de Cuba; Geert Kazemier; Elisabeth A Te Velde Journal: Ann Surg Date: 2016-06 Impact factor: 12.969
Authors: J-B Delhorme; C Honoré; L Benhaim; F Dumont; P Dartigues; C Dromain; M Ducreux; D Elias; D Goéré Journal: Eur J Surg Oncol Date: 2016-09-02 Impact factor: 4.424
Authors: Patricio M Polanco; Ying Ding; Jordan M Knox; Lekshmi Ramalingam; Heather Jones; Melissa E Hogg; Amer H Zureikat; Matthew P Holtzman; James Pingpank; Steven Ahrendt; Herbert J Zeh; David L Bartlett; Haroon A Choudry Journal: Ann Surg Oncol Date: 2015-10-01 Impact factor: 5.344
Authors: Sean P Dineen; Richard E Royal; Marybeth S Hughes; Tara Sagebiel; Priya Bhosale; Michael Overman; Aurelio Matamoros; Paul F Mansfield; Keith F Fournier Journal: Ann Surg Oncol Date: 2015-02-20 Impact factor: 5.344
Authors: Mohammad Breakeit; Daniel Liu; Adrian Cheng; Hyerim Suh; Shoma Barat; Amer Matar; Nayef Alzahrani; David L Morris Journal: In Vivo Date: 2022 Sep-Oct Impact factor: 2.406